Aptose Biosciences, Inc. (NASDAQ:APTO) a clinical-stage biotechnology company, is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020.
Previous Quarter Performance
Aptose Biosciences, Inc. disclosed loss for the first quarter of $ 0.15 per share, from the revenue of . The quarterly revenues compared with the same quarter last year. Wall street analysts are predicting, loss of $ 0.15 per share The bottom line results street analysts by $ 0 or , at the same time, top line results analysts by $ 1.99 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of APTO was $ 5.20, representing a 185.71 % increase from the 52 week low of $ 1.82 and a 43.78 % decrease over the 52 week high of $ 9.25.
The company has a market capital of $ 448.01 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”APTO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Aptose Biosciences, Inc. will be hosting a conference call at 5:00 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.aptose.com
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc.
